Geraniin (Synonyms: NSC 359346) |
|
Catalog No.GN10151
|
Geraniin, a TNF-α releasing inhibitor with an IC50 value of 43μM, exhibits numerous activities including anticancer, anti-inflammatory, and anti-hyperglycemic activities.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 60976-49-0
Sample solution is provided at 25 µL, 10mM.
Geraniin, a TNF-α releasing inhibitor with an IC50 value of 43μM, exhibits numerous activities including anticancer, anti-inflammatory, and anti-hyperglycemic activities[1]. Geraniin can induce the nuclear translocation of nuclear factor Nrf2 and enhance glutathione (GSH) levels, thus reducing intracellular ROS levels in cells [2]. Geraniin has been widely used in cell and animal models to inhibit tumor growth and interfere with mitochondrial function[3].
In vitro, Geraniin treatment for 48 hours significantly inhibited the viability of OVCAR3 and SKOV3 cells with IC50 values of 34.5μM and 23.6μM, respectively[4]. Geraniin treatment at 36µM for 24h abrogated HT-29 cell growth and induced nuclear morphological changes and DNA fragmentation[5]. Treatment of T24 cells with 20µM Geraniin for 24 hours induced cell cycle arrest, decreased the proportion of T24 cells in S phase, promoted cell apoptosis, and regulated the PI3K/AKT signaling pathway[6].
In vivo, Geraniin (20mg/kg/day) administered daily by gavage for 14 days alleviated lipopolysaccharide (LPS)-induced cognitive impairment, ameliorated LPS-induced nerve/synaptic damage, and reduced Aβ production in mice[7]. Daily gavage administration of Geraniin (8mg/kg/day) for 10 consecutive weeks could reduce the body weight of ApoE−/− mice on a high-fat diet, and lower the levels of serum triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C)[8].
References:
[1] Okabe S, Suganuma M, Imayoshi Y, et al. New TNF-α releasing inhibitors, geraniin and corilagin, in leaves of Acer nikoense, Megusurino-ki[J]. Biological and Pharmaceutical Bulletin, 2001, 24(10): 1145-1148.
[2] Cheng H S, Ton S H, Abdul Kadir K. Ellagitannin geraniin: a review of the natural sources, biosynthesis, pharmacokinetics and biological effects[J]. Phytochemistry reviews, 2017, 16(1): 159-193.
[3] Li J, Wang S, Yin J, et al. Geraniin induces apoptotic cell death in human lung adenocarcinoma A549 cells in vitro and in vivo[J]. Canadian Journal of Physiology and Pharmacology, 2013, 91(12): 1016-1024.
[4] Wang X, Chen Z, Li X, et al. Geraniin suppresses ovarian cancer growth through inhibition of NF‐κB activation and downregulation of Mcl‐1 expression[J]. Journal of Biochemical and Molecular Toxicology, 2017, 31(9): e21929.
[5] Chan C K, Tang L Y, Goh B H, et al. Targeting apoptosis via inactivation of PI3K/Akt/mTOR signaling pathway involving NF-κB by geraniin in HT-29 human colorectal adenocarcinoma cells[J]. Progress in Drug Discovery & Biomedical Science, 2019, 2(1).
[6] Xu J, Qin N, Yao Y, et al. Geraniin inhibits bladder cancer cell growth via regulation of PI3K/AKT signaling pathways[J]. Tropical Journal of Pharmaceutical Research, 2020, 19(2): 253-257.
[7] Wang D, Dong X, Wang B, et al. Geraniin attenuates lipopolysaccharide-induced cognitive impairment in mice by inhibiting toll-like receptor 4 activation[J]. Journal of Agricultural and Food Chemistry, 2019, 67(36): 10079-10088.
[8] Xie Y, Liu S, Wei Z, et al. Geraniin Alleviates High‐Fat Diet‐Induced Atherosclerosis in ApoE−/− Mice[J]. Food Science & Nutrition, 2025, 13(7): e70693.
| Cell experiment [1]: | |
Cell lines | OVCAR3 cells |
Preparation Method | OVCAR3 cells were cultured in Dulbecco's Modified Eagle's medium containing 10% fetal bovine serum at 37℃ in the presence of 5% CO2. OVCAR3 cells were seeded at a density of 5×103 cells/well in 96-well flat-bottom plates and cultured for 24 hours. Cells were treated with different concentrations of Geraniin (0, 5, 10, 20, 40, and 80µM), and the cell viability was detected after 48 hours. |
Reaction Conditions | 0, 5, 10, 20, 40, and 80µM; 48h |
Applications | Geraniin treatment reduced the cell viability of OVCAR3 cells in a concentration-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male ApoE−/− mice |
Preparation Method | Male ApoE−/− mice (six weeks old) were housed in a Specific Pathogen-Free (SPF) experimental environment, with the temperature set at 24°C±1°C, relative humidity controlled between 40% and 50%, and exposed to a 12-h light–dark cycle. All mice were adaptively fed for one week. The ApoE−/− mice were randomly assigned to one of 2 groups (n=6 per group): (1) ApoE−/− mice model group; (2) Geraniin 8mg/kg/day (p.o.). All ApoE−/− mice were fed a high-fat diet (40% kcal fat) containing 0.5% cholesterol for 10 weeks. Mice were weighed weekly, and blood was collected for analysis. |
Dosage form | 8mg/kg/day for 10 weeks; p.o. |
Applications | Geraniin treatment reduced the body weight of ApoE−/− mice on a high-fat diet, and decreased the levels of TG and LDL-C. |
References: | |
| Cas No. | 60976-49-0 | SDF | |
| Synonyms | NSC 359346 | ||
| Canonical SMILES | OC1=C(O)C(O)=C(C(C(O)=C(O)C(O)=C2)=C2C(O[C@H]3[C@@H]4OC(C(C=C(O)C(O)=C5OC6(O)C(O)7O)=C5C7C8=CC6=O)=O)=O)C(C(OC[C@H](O[C@@H]4OC(C9=CC(O)=C(O)C(O)=C9)=O)[C@@H]3OC8=O)=O)=C1 | ||
| Formula | C41H28O27 | M.Wt | 952.08 |
| Solubility | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2) (1:3): 0.25 mg/ml | Storage | 4°C, away from moisture and light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.0503 mL | 5.2517 mL | 10.5033 mL |
| 5 mM | 210.1 μL | 1.0503 mL | 2.1007 mL |
| 10 mM | 105 μL | 525.2 μL | 1.0503 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)















